{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:48:26Z","timestamp":1784551706099,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012733","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,6,3]],"date-time":"2018-06-03T00:00:00Z","timestamp":1527984000000}}],"reference-count":177,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012733.pub2","type":"journal-article","created":{"date-parts":[[2018,6,3]],"date-time":"2018-06-03T22:51:22Z","timestamp":1528066282000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Continuous versus intermittent antibiotics for bronchiectasis"],"prefix":"10.1002","volume":"2018","author":[{"given":"Tim","family":"Donovan","sequence":"first","affiliation":[{"name":"University of Cumbria; Medical and Sport Sciences; Lancaster UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert M","family":"Felix","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS); Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D","family":"Chalmers","sequence":"additional","affiliation":[{"name":"University of Dundee, Ninewells Hospital and Medical School; Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Milan","sequence":"additional","affiliation":[{"name":"Lancaster University; Medical School; Lancaster UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G","family":"Mathioudakis","sequence":"additional","affiliation":[{"name":"University of Manchester; Division of Infection, Immunity and Respiratory Medicine; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Spencer","sequence":"additional","affiliation":[{"name":"Edge Hill University; Postgraduate Medical Institute; St Helens Road Ormskirk Lancashire UK L39 4QP"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,3]]},"reference":[{"key":"10.1002\/14651858.CD012733.pub2-BIB0001|cit1","first-page":"A1768","article-title":"Baseline demographic profile of subjects of the phase 3 RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB)","volume":"193","author":"Aksamit","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Aksamit T Bandel TJ Criollo M De Soyza A Elborn JS Operschall E The RESPIRE trials: two phase III, randomized, multicentre, placebo-controlled trials of ciprofloxacin dry powder for inhalation (ciprofloxacin dpi) in non-cystic fibrosis bronchiectasis Contemporary Clinical Trials 2017 78 85","DOI":"10.1016\/j.cct.2017.05.007"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0003|cit3","first-page":"A7642","article-title":"Respire 2: ciprofloxacin dpi 32.5 mg b.i.d. administered 14 days on\/off or 28 days on\/off vs. placebo for 48 weeks in patients with non-cystic fibrosis bronchiectasis (NCFB)","volume":"195","author":"Aksamit","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0004|cit4","first-page":"PA2617","article-title":"Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB)","volume":"46","author":"Soyza","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0005|cit5","first-page":"OA272","article-title":"RESPIRE 1: ciprofloxacin DPI 32.5mg b.d. administered 14 day on\/off or 28 day on\/off vs placebo for 48 weeks in subjects with non-cystic fibrosis bronchiectasis (NCFB)","volume":"48","author":"Soyza","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0006|cit6","unstructured":"NCT01764841 Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non-cf BE) clinicaltrials.gov\/ct2\/show\/NCT01764841"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0007|cit7","unstructured":"NCT02106832 Ciprofloxacin dry powder for inhalation (dpi) in non-cystic fibrosis bronchiectasis (non-CF BE) (RESPIRE 2) clinicaltrials.gov\/ct2\/show\/NCT02106832"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0008|cit8","first-page":"A7303","article-title":"Effects of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) on health-related quality of life in patients with non-cystic fibrosis bronchiectasis (NCFB): results from the Phase III RESPIRE 1 study","volume":"195","author":"Quittner","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"53","key":"10.1002\/14651858.CD012733.pub2-BIB0009|cit9","first-page":"2995","article-title":"Studies of the clinical and respiratory functional effects of a mucolytic-antibiotic preparation in chronic bronchopulmonary diseases. Controlled double-blind single code studies","volume":"59","author":"Alberto","year":"1968","journal-title":"Minerva Medica"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0010|cit10","first-page":"44","article-title":"Direct current in the overall treatment of inflammatory suppurative diseases of the lungs","volume":"2","author":"Alekseenko","year":"1978","journal-title":"Fizicheskoi Kultury"},{"issue":"1","key":"10.1002\/14651858.CD012733.pub2-BIB0011|cit11","first-page":"57","article-title":"Effectiveness of conservative treatment of disseminated forms of chronic inflammatory-suppurative lung diseases","volume":"52","author":"Alekseenko","year":"1980","journal-title":"Terapevticheskii Arkhiv"},{"issue":"3","key":"10.1002\/14651858.CD012733.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1183\/13993003.01888-2015","article-title":"Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration","volume":"48","author":"Aliberti","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD012733.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.5144\/0256-4947.1998.469","article-title":"Pseudomonas aeruginosa in hospitalized patients with infective exacerbations of bronchiectasis: clinical and research implications","volume":"18","author":"Al-Mobeireek","year":"1998","journal-title":"Annals of Saudi Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012733.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1517\/13543784.2013.783565","article-title":"Ciprofloxacin dpi in non-cystic fibrosis bronchiectasis: a phase II randomized study","volume":"22","author":"Antoniu","year":"2013","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"3","key":"10.1002\/14651858.CD012733.pub2-BIB0015|cit15","first-page":"345","article-title":"Long-term treatment of bronchiectasis and chronic bronchitis; a controlled study of the effects of tetracycline, penicillin, and an oleandomycinpenicillin mixture","volume":"103","author":"Cherniack","year":"1959","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0016|cit16","unstructured":"ChiCTR-IOR-16008910 Effectiveness of procalcitonin-guided antibiotic therapy in acute exacerbations of bronchiectasis: a randomized controlled trial www.chictr.org.cn\/showprojen.aspx?proj=15079"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0017|cit17","unstructured":"Chonabayasi N Aosima M Noguchi M Yoshimura K Nakatani T Nakamori Y T-3262 in respiratory infections Chemotherapy 1988 439 53"},{"issue":"2","key":"10.1002\/14651858.CD012733.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"e00103","DOI":"10.1128\/mSphere.00103-18","article-title":"Impact of long-term erythromycin therapy on the oropharyngeal microbiome and resistance gene reservoir in non-cystic fibrosis bronchiectasis","volume":"3","author":"Choo","year":"2018","journal-title":"mSphere"},{"issue":"3","key":"10.1002\/14651858.CD012733.pub2-BIB0019|cit19","first-page":"115","article-title":"Treatment with sumetrolim in chronic non-specific respiratory tract infections","volume":"23","author":"Cseri","year":"1975","journal-title":"Therapia Hungarica"},{"issue":"s16","key":"10.1002\/14651858.CD012733.pub2-BIB0020|cit20","first-page":"79P","article-title":"Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis [abstract]","volume":"72","author":"Currie","year":"1987","journal-title":"Clinical Research"},{"issue":"6590","key":"10.1002\/14651858.CD012733.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/bmj.295.6590.119-a","article-title":"Penetration of antibiotics into the respiratory tract","volume":"295","author":"Currie","year":"1987","journal-title":"British Medical Journal (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0022|cit22","first-page":"OA1971","article-title":"Eradication treatment in Non CF bronchiectasis: the effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa","volume":"suppl 61","author":"Dimakou","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0023|cit23","first-page":"A1518","article-title":"Non cf bronchiectasis: the effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa in sputum","volume":"195","author":"Dimakou","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6988","key":"10.1002\/14651858.CD012733.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0140-6736(57)91597-0","article-title":"Effect of antibiotics on purulent sputum in chronic bronchitis and bronchiectasis","volume":"273","author":"Douglas","year":"1957","journal-title":"Lancet"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD012733.pub2-BIB0025|cit25","first-page":"565","article-title":"Basic and clinical studies on cefdinir","volume":"37","author":"Hayashi","year":"1989","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0026|cit26","first-page":"142s","article-title":"Sputum and serum pharmacokinetics of loracarbef (a new carbacephem antibiotic) in patients with bronchiectasis [Abstract]","volume":"5","author":"Hill","year":"1992","journal-title":"European Respiratory Journal"},{"issue":"6040","key":"10.1002\/14651858.CD012733.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1136\/bmj.2.6040.882-c","article-title":"Antibiotics and purulent sputum","volume":"2","author":"Howie","year":"1976","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"Article Number:","DOI":"10.1155\/2018\/5813767","article-title":"Investigation into the individualized treatment of traditional chinese medicine through a series of n-of-1 trials","volume":"2018","author":"Huang","year":"2018","journal-title":"Evidence-based Complementary and Alternative Medicine : ECAM"},{"issue":"Suppl","key":"10.1002\/14651858.CD012733.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/infdis\/128.Supplement_3.S701","article-title":"Use of combinations of trimethoprim and sulfamethoxazole in the treatment of chest infections","volume":"128","author":"Hughes","year":"1973","journal-title":"Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD012733.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5694\/j.1326-5377.1973.tb111191.x","article-title":"Use of combinations of trimethoprim and sulphamethoxazole in the treatment of chest infections","volume":"1","author":"Hughes","year":"1973","journal-title":"Medical Journal of Australia"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0031|cit31","unstructured":"Iglauer E Wieser O Parenteral treatment of severe bronchopulmonary infections using trimethoprim and sulfamethoxazole Wiener Medizinische Wochenschrift (1946) 1973 322 3"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0032|cit32","first-page":"285","article-title":"Basic and clinical studies on 7432-S. [Japanese]","volume":"37","author":"Inoue","year":"1989","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0033|cit33","first-page":"603","article-title":"Laboratory and clinical studies on cefdinir. [Japanese]","volume":"37","author":"Irabu","year":"1989","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0034|cit34","first-page":"452","article-title":"Laboratory and clinical studies of ME1207. [Japanese]","volume":"40","author":"Irabu","year":"1992","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0035|cit35","first-page":"819s","article-title":"The effects of roxithromycin as anti-inflammatory agent on clinical outcomes in patient with bronchiectasis: A double blinded randomized controlled study [Abstract]","volume":"38","author":"Juthong","year":"2011","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0036|cit36","first-page":"25","article-title":"Clinical trial use of phenoxypropyl penicillin","volume":"16","author":"Kanai","year":"1963","journal-title":"Journal of Antibiotics"},{"issue":"4","key":"10.1002\/14651858.CD012733.pub2-BIB0037|cit37","first-page":"446","article-title":"Studies on amikacin (BB-K8), a new aminoglycoside antibiotic (author's transl)","volume":"27","author":"Kawano","year":"1974","journal-title":"Japanese Journal of Antibiotics"},{"issue":"6","key":"10.1002\/14651858.CD012733.pub2-BIB0038|cit38","first-page":"1268","article-title":"Clinical role of Branhamella catarrhalis infection in pulmonary disorders. [Japanese]","volume":"44","author":"Kawashima","year":"1989","journal-title":"Saishin Igaku [Modern Medicine]"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0039|cit39","first-page":"692","article-title":"ME1207: a clinical study. [Japanese]","volume":"40","author":"Koyama","year":"1992","journal-title":"Chemotherapy"},{"issue":"25","key":"10.1002\/14651858.CD012733.pub2-BIB0040|cit40","first-page":"927","article-title":"Comparative evaluation of certain antibiotics and Biceptol preparation in the treatment of chronic bronchial disease exacerbations. [Polish]","volume":"36","author":"Krawczyk","year":"1981","journal-title":"Polski Tygodnik Lekarski"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0041|cit41","first-page":"696","article-title":"ME1207 in respiratory infections. [Japanese]","volume":"40","author":"Kudo","year":"1992","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0042|cit42","first-page":"273","article-title":"Basic and clinical studies on cefclidin. [Japanese]","volume":"40","author":"Kurishima","year":"1992","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0043|cit43","first-page":"467","article-title":"Cefodizime (THR-221) in respiratory tract infections. [Japanese]","volume":"36","author":"Kuze","year":"1988","journal-title":"Chemotherapy"},{"issue":"14","key":"10.1002\/14651858.CD012733.pub2-BIB0044|cit44","first-page":"969","article-title":"Bronchiectasis [French]","volume":"34","author":"Lamotte","year":"1981","journal-title":"Ouest-medical"},{"issue":"1","key":"10.1002\/14651858.CD012733.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/thorax.55.1.91a","article-title":"Nebulised taurolidine and B cepacia bronchiectasis","volume":"55","author":"Ledson","year":"2000","journal-title":"Thorax"},{"issue":"12","key":"10.1002\/14651858.CD012733.pub2-BIB0046|cit46","first-page":"1123","article-title":"Intratracheal use of morphocycline. [Russian]","volume":"13","author":"Lunacharskaia","year":"1968","journal-title":"Antibiotiki"},{"issue":"2","key":"10.1002\/14651858.CD012733.pub2-BIB0047|cit47","first-page":"140","article-title":"Clinical results of the use of cephaloridine in lung diseases, especially pulmonary tuberculosis. [Japanese]","volume":"20","author":"Maekawa","year":"1967","journal-title":"Journal of Antibiotics. Ser. B"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0048|cit48","first-page":"331","article-title":"A clinical study of cefclidin","volume":"40","author":"Masuno","year":"1992","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0049|cit49","first-page":"397","article-title":"Laboratory and clinical evaluation of lenampicillin (KBT-1585) in respiratory infection. [Japanese]","volume":"32","author":"Matsumoto","year":"1984","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0050|cit50","first-page":"740","article-title":"Clinical studies on ME1207 in the treatment of respiratory tract infections. [Japanese]","volume":"40","author":"Matsumoto","year":"1992","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0051|cit51","first-page":"795","article-title":"Clinical studies of S-1108 in elderly patients","volume":"41","author":"Matsuura","year":"1993","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0052|cit52","first-page":"85","article-title":"Amoxicillin in the treatment of lower respiratory infections","volume":"7","author":"May","year":"1974","journal-title":"Advances in Clinical Pharmacology"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003495-199300453-00176","article-title":"Ciprofloxacin in the treatment of lower respiratory tract infections","volume":"46","author":"Mazzei","year":"1993","journal-title":"Drugs"},{"issue":"2","key":"10.1002\/14651858.CD012733.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/17843286.1973.11716858","article-title":"Double-blind study of the sulfamethoxazole-trimethoprim association in the treatment of pulmonary infections","volume":"28","author":"Messens","year":"1973","journal-title":"Acta Clinica Belgica"},{"issue":"3","key":"10.1002\/14651858.CD012733.pub2-BIB0055|cit55","first-page":"20","article-title":"Antibacterial treatment of anaerobic lung infections. [Bulgarian]","volume":"22","author":"Milcev","year":"1985","journal-title":"Pnevmologiya i Ftiziatriya"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0056|cit56","first-page":"A168","article-title":"Efficacy of macrolide and theophylline in the management of bronchiectasis","volume":"10","author":"Ming","year":"2005","journal-title":"Respirology"},{"issue":"11","key":"10.1002\/14651858.CD012733.pub2-BIB0057|cit57","first-page":"90","article-title":"Cleansing of the bronchial tree in treating chronic inflammatory lung diseases. [Russian]","volume":"11","author":"Molodtsova","year":"1980","journal-title":"Sovetskaia Meditsina"},{"issue":"4","key":"10.1002\/14651858.CD012733.pub2-BIB0058|cit58","first-page":"253","article-title":"Pulmonary infections in adults: two therapeutics regimens of ofloxacin","volume":"98","author":"Morrone","year":"1989","journal-title":"Folha Medica"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0059|cit59","first-page":"724","article-title":"A clinical study of the effects of ME1207 on respiratory infections [Japanese]","volume":"40","author":"Murayama","year":"1992","journal-title":"Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD012733.pub2-BIB0060|cit60","first-page":"283","article-title":"Late results of the conservative treatment of bronchiectasis in adults. [German]","volume":"127","author":"Nagy","year":"1968","journal-title":"Zeitschrift fur Tuberkulose und Erkrankungen der Thoraxorgane"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0061|cit61","unstructured":"Nakagawa Y Niki Y Hino J Kishimoto T Kawane H Soejima R Bacteriological and clinical studies of cefdinir Chemotherapy 1989 518 24"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0062|cit62","first-page":"803","article-title":"Clinical study of S-1108 in respiratory infections","volume":"41","author":"Nakagawa","year":"1993","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0063|cit63","first-page":"699","article-title":"T-3262 in respiratory tract infections [Japanese]","volume":"36","author":"Nasu","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0064|cit64","unstructured":"NCT00415350 Bronchiectasis and long term azithromycin treatment clinicaltrials.gov\/ct2\/show\/NCT00415350"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0065|cit65","unstructured":"NCT00524095 Bronchiectasis in chronic obstructive pulmonary disease (COPD) patients: role of prophylaxis clinicaltrials.gov\/ct2\/show\/NCT00524095"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0066|cit66","unstructured":"NCT00775138 A study to determine the safety and tolerability of arikace versus placebo in patients who have bronchiectasis clinicaltrials.gov\/ct2\/show\/NCT00775138"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0067|cit67","unstructured":"NCT00889967 Safety and efficacy study of ciprofloxacin for inhalation in patients with non-cystic fibrosis bronchiectasis \"ORBIT-1\" clinicaltrials.gov\/ct2\/show\/NCT00889967"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0068|cit68","unstructured":"NCT00930982 Evaluation of cipro inhale in patients with non-cystic fibrosis bronchiectasis clinicaltrials.gov\/ct2\/show\/NCT00930982"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0069|cit69","unstructured":"NCT01313624 A study to see if AZLI (an inhaled antibiotic) is effective in treating adults with non-cf bronchiectasis - AIR-BX1 clinicaltrials.gov\/ct2\/show\/NCT01313624"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0070|cit70","unstructured":"NCT01515007 Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3) ClinicalTrials.gov 2012"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0071|cit71","unstructured":"NCT01538667 Study to characterize lung deposition, pharmacokinetics, safety and tolerability of single inhalations of radiolabeled ciprofloxacin dry powder in healthy subjects and patients with chronic lung diseases clinicaltrials.gov\/ct2\/show\/NCT01538667"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0072|cit72","unstructured":"NCT01761214 Bacteriology and inflammation in bronchiectasis clinicaltrials.gov\/ct2\/show\/NCT01761214"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0073|cit73","unstructured":"NCT02035488 Pharmacokinetic evaluation and tolerability of dry powder tobramycin by a novel device in patients with non cystic fibrosis bronchiectasis clinicaltrials.gov\/ct2\/show\/NCT02035488"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0074|cit74","unstructured":"NCT02047773 Bacterial load guided therapy for severe bronchiectasis exacerbations clinicaltrials.gov\/ct2\/show\/NCT02047773"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0075|cit75","unstructured":"NCT02081963 Combined administration of nebulized amikacin in patients with acute exacerbation of non-cystic fibrosis bronchiectasis clinicaltrials.gov\/ct2\/show\/NCT02081963"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0076|cit76","unstructured":"NCT02102152 Efficacy & tolerability of tobramycin podhaler in bronchiectasis patients with chronic pseudomonas aeruginosa infection clinicaltrials.gov\/ct2\/show\/NCT02102152"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0077|cit77","unstructured":"NCT02104245 Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4) ClinicalTrials.gov 2014"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0078|cit78","unstructured":"NCT02107274 Efficacy of azithromycin in treatment of bronchiectasis clinicaltrials.gov\/ct2\/show\/NCT02107274"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0079|cit79","unstructured":"NCT02315547 Sputum microbiota and the association with clinical parameters in steady-state, acute exacerbation and convalescence of bronchiectasis (BISER-2) clinicaltrials.gov\/ct2\/show\/NCT02315547"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0080|cit80","unstructured":"NCT02491723 Macrolide mediates pulmonary infection of pseudomonas aeruginosa clinicaltrials.gov\/ct2\/show\/NCT02491723"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0081|cit81","unstructured":"NCT02509091 Therapy of bronchoalveolar lavage and local amikacin injection in patients with acute exacerbation of bronchiectasis clinicaltrials.gov\/ct2\/show\/NCT02509091"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0082|cit82","unstructured":"NCT02657473 Inhaled nebulized tobramycin in non-cystic fibrosis bronchiectasis (BATTLE) clinicaltrials.gov\/ct2\/show\/NCT02657473"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0083|cit83","unstructured":"NCT02661438 Summative usability study of ciprofloxacin dry powder for inhalation using placebo clinicaltrials.gov\/ct2\/show\/NCT02661438"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0084|cit84","unstructured":"NCT03058718 Procalcitonin-guided antibiotic therapy in bronchiectasis clinicaltrials.gov\/ct2\/show\/NCT03058718"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0085|cit85","unstructured":"NCT03093974 Trial in non-cystic fibrosis bronchiectasis patients with chronic lung infections treated with colistimethate sodium (PROMIS-I) clinicaltrials.gov\/ct2\/show\/NCT03093974"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0086|cit86","unstructured":"Trial in non-cystic fibrosis bronchiectasis patients with chronic lung infections treated with colistimethate sodium (PROMIS-2) https:\/\/clinicaltrials.gov\/show\/NCT03460704"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1159\/000220158","article-title":"Clinical trials of the new antibiotic, rifamycin sv: preliminary report","volume":"12","author":"Neumayr","year":"1963","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0088|cit88","first-page":"A1775","article-title":"ORBIT-3 and ORBIT-4: design of a phase 3 program to investigate safety and efficacy of pulmaquin in non-cystic fibrosis bronchiectasis (NCFBE) patients chronically colonized with pseudomonas aeruginosa (PA)","volume":"193","author":"O'Donnell","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0089|cit89","first-page":"700","article-title":"Clinical study on ME1207 in respiratory tract infections","volume":"40","author":"Obana","year":"1992","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0090|cit90","first-page":"703","article-title":"Clinical study of ME 1207 in respiratory tract infections","volume":"40","author":"Odagiri","year":"1992","journal-title":"Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD012733.pub2-BIB0091|cit91","first-page":"15","article-title":"Therapeutic effect of amikacin for infections with gram-negative bacilli, especially for stubborn respiratory infections (author's transl). [Japanese]","volume":"31","author":"Oizumi","year":"1978","journal-title":"Japanese Journal of Antibiotics"},{"issue":"1","key":"10.1002\/14651858.CD012733.pub2-BIB0092|cit92","first-page":"17","article-title":"Clinical study of a new cephalosporin: ceftriaxone (RO 13-9904) in resurgent acute and chronic bronchopneumopathies. [Italian]","volume":"38","author":"Pezza","year":"1983","journal-title":"Archivio Monaldi per la Tisiologia e le Malattie dell'Apparato Respiratorio"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0093|cit93","first-page":"715","article-title":"Preclinical and clinical studies on TE-031 (A-56268) in treatment of bacterial respiratory tract infections","volume":"36","author":"Rikitomi","year":"1988","journal-title":"Chemotherapy"},{"issue":"11","key":"10.1002\/14651858.CD012733.pub2-BIB0094|cit94","first-page":"1232","article-title":"A study of the clinical effects of clindamycin on respiratory infections - Focusing on inhibition of beta-lactamase production. [Japanese]","volume":"41","author":"Saito","year":"1993","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0095|cit95","first-page":"42","article-title":"Effectiveness of inhaled antibiotic treatment for pseudomonas aeruginosa in outpatients with colonized bronchiectasis without mucoviscidosis","volume":"31","author":"Santiveri","year":"1995","journal-title":"Archivos de Bronconeumologia"},{"issue":"2","key":"10.1002\/14651858.CD012733.pub2-BIB0096|cit96","first-page":"185","article-title":"Comparative studies on the toxicity of tetracyclines and chloramphenicol in the treatment of nonspecific bronchopulmonary infections. [German]","volume":"136","author":"Schulz","year":"1972","journal-title":"Zeitschrift fur Erkrankungen der Atmungsorgane Mit Folia Bronchologica"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0097|cit97","first-page":"334s","article-title":"Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE) [Abstract]","volume":"28","author":"Serisier","year":"2011","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0098|cit98","first-page":"1697","article-title":"Macrolide treatment inhibits pseudomonas aeruginosa quorum sensing in non-cystic fibrosis bronchiectasis: an analysis from the bronchiectasis and low-dose erythromycin study trial","volume":"13","author":"Burr","year":"2016","journal-title":"Annals of the American Thoracic Society"},{"issue":"4","key":"10.1002\/14651858.CD012733.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2213-2600(15)00102-2","article-title":"Corrections to, The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial","volume":"3","author":"Rogers","year":"2015","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0100|cit100","first-page":"A6862","article-title":"The bronchiectasis and low-dose erythromycin study (BLESS) [Abstract]","volume":"185","author":"Serisier","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0101|cit101","first-page":"382","article-title":"Laboratory and clinical studies on lenampicillin (KBT-1585) a new penicillin antibiotic. [Japanese]","volume":"32","author":"Shigeno","year":"1984","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0102|cit102","unstructured":"Shimada K Inamatsu T Fukayama M Kato A Adachi K Sasaki M Antimicrobial activity and clinical evaluation of NY-198 Chemotherapy 1988 537 44"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0103|cit103","first-page":"748","article-title":"Evaluation of cefclidin on respiratory tract infections","volume":"40","author":"Shimokata","year":"1992","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00003495-199500492-00126","article-title":"Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections","volume":"49","author":"Shishido","year":"1995","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0105|cit105","first-page":"PA4063","article-title":"Open label case-control study to assess Pidotimod efficacy in Non CF Bronchiectasis Disease: a pilot study","volume":"50","author":"Simioli","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0106|cit106","first-page":"673","article-title":"Clinical studies on TE-031 (A-56268)","volume":"36","author":"Soejima","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0107|cit107","first-page":"694","article-title":"Clinical studies of T-3262 in respiratory tract infection. [Japanese]","volume":"36","author":"Suga","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0108|cit108","first-page":"167","article-title":"Efficacy of Juqin mixture aerosol inhalation treatment of bronchiectasis","volume":"21","author":"Sun","year":"2015","journal-title":"Chinese Journal of Experimental Traditional Medical Formulae"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0109|cit109","first-page":"529","article-title":"Laboratory and clinical studies on cefodizime (THR-221)","volume":"36","author":"Suyama","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0110|cit110","first-page":"33","article-title":"Effect and action mechanism of short-term administration of clarithromycin for airway hypersecretion. [Japanese]","volume":"54","author":"Tagaya","year":"2001","journal-title":"Japanese Journal of Antibiotics"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0111|cit111","first-page":"737","article-title":"Clinical studies on cefclidin","volume":"40","author":"Tamura","year":"1992","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0112|cit112","first-page":"683","article-title":"A clinical study on ME1207 in respiratory infections","volume":"40","author":"Tanimoto","year":"1992","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0113|cit113","first-page":"751","article-title":"Clinical studies on S-1108 in respiratory infections","volume":"41","author":"Tanimoto","year":"1993","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0114|cit114","first-page":"A76","article-title":"Nebulised antibiotics reduce symptoms, bacterial density and oral antibiotic usage in children with non cystic fibrosis bronchiectasis [Abstract]","volume":"14","author":"Twiss","year":"2009","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0115|cit115","first-page":"708","article-title":"Clinical study of ME1207","volume":"40","author":"Wada","year":"1992","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0116|cit116","first-page":"311","article-title":"Basic and clinical studies on cefotiam hexetil","volume":"36","author":"Watanabe","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1007\/BF01715833","article-title":"Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease","volume":"19","author":"Watanabe","year":"1991","journal-title":"Infection"},{"issue":"1","key":"10.1002\/14651858.CD012733.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1620\/tjem.176.25","article-title":"Daily single-dose regimen and alternate-two-week triple-dose\/day regimen of oral ofloxacin for the prophylaxis and control of exacerbations of chronic respiratory tract infections","volume":"176","author":"Watanabe","year":"1995","journal-title":"Tohoku Journal of Experimental Medicine"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"Weston M A clinical trial of fusafungin British Journal of Diseases of the Chest 1966 104 6","DOI":"10.1016\/S0007-0971(66)80007-4"},{"issue":"55","key":"10.1002\/14651858.CD012733.pub2-BIB0120|cit120","first-page":"334s","article-title":"Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis [Abstract]","volume":"38","author":"Wilson","year":"2011","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0121|cit121","first-page":"A135","article-title":"Quality of life effect of levofloxacin compared to ceftazidime treatment in infective exacerbation of bronchiectasis [Abstract]","volume":"9","author":"Wong","year":"2004","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0122|cit122","first-page":"816","article-title":"Clinical study on S-1108 in respiratory tract infections","volume":"41","author":"Yamada","year":"1993","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0123|cit123","first-page":"579","article-title":"Basic and clinical evaluation of cefdinir, a new oral cephem","volume":"37","author":"Yoshida","year":"1989","journal-title":"Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD012733.pub2-BIB0124|cit124","first-page":"401","article-title":"Study of doxycycline in pleuropulmonary affections","volume":"59","author":"Zegaya","year":"1981","journal-title":"La Tunisie Medicale"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0125|cit125","unstructured":"Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection (iBEST-1) Ongoing study"},{"issue":"12","key":"10.1002\/14651858.CD012733.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD012733.pub2-BIB0127|cit127","first-page":"738","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet"},{"issue":"1421","key":"10.1002\/14651858.CD012733.pub2-BIB0128|cit128","first-page":"30","article-title":"Hospital admissions for non-cystic fibrosis bronchiectasis in New Zealand","volume":"128","author":"Bibby","year":"2015","journal-title":"New Zealand Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD012733.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"7","key":"10.1002\/14651858.CD012733.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012733.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.molimm.2012.09.011","article-title":"Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis","volume":"55","author":"Chalmers","year":"2013","journal-title":"Molecular Immunology"},{"issue":"5","key":"10.1002\/14651858.CD012733.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The bronchiectasis severity index. An international derivation and validation study","volume":"189","author":"Chalmers","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012733.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1183\/09031936.00119114","article-title":"Management of bronchiectasis in adults","volume":"45","author":"Chalmers","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD012733.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"200","DOI":"10.5694\/j.1326-5377.2002.tb04733.x","article-title":"Bronchiectasis in indigenous children in remote Australian communities","volume":"177","author":"Chang","year":"2002","journal-title":"Medical Journal of Australia"},{"issue":"6","key":"10.1002\/14651858.CD012733.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5694\/j.1326-5377.2010.tb03949.x","article-title":"Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand","volume":"193","author":"Chang","year":"2010","journal-title":"Medical Journal of Australia"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0136|cit136","first-page":"6","article-title":"Inflammation: a two-edged sword - the model of bronchiectasis","volume":"147","author":"Cole","year":"1986","journal-title":"European Journal of Respiratory Diseases. Supplement"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/40.suppl_1.5","article-title":"The damaging role of bacteria in chronic lung infection","volume":"40 Suppl A","author":"Cole","year":"1997","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD012733.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/1479972316643698","article-title":"Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence","volume":"13","author":"Rosa","year":"2016","journal-title":"Chronic Respiratory Disease"},{"issue":"9237","key":"10.1002\/14651858.CD012733.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD012733.pub2-BIB0140|cit140","first-page":"1","article-title":"Comparison of inhaled antibiotics for the treatment of chronic pseudomonas aeruginosa lung Infection in patients with cystic fibrosis: systematic literature review and network meta-analysis","volume":"8","author":"Elborn","year":"2016","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0141|cit141","doi-asserted-by":"crossref","DOI":"10.1183\/09031936.00105513","article-title":"European Lung White Book: Respiratory Health and Disease in Europe","volume-title":"European Lung White Book: Respiratory Health and Disease in Europe","author":"Gibson","year":"2013"},{"issue":"8","key":"10.1002\/14651858.CD012733.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1183\/09031936.96.09081601","article-title":"Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa","volume":"9","author":"Evans","year":"1996","journal-title":"European Respiratory Journal"},{"issue":"11","key":"10.1002\/14651858.CD012733.pub2-BIB0143|cit143","first-page":"1602","article-title":"A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis","volume":"12","author":"Finch","year":"2015","journal-title":"Annals of the American Thoracic Society"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0144|cit144","first-page":"68","article-title":"Microbiology of non-CF bronchiectasis","volume-title":"European Respiratory Society Monographs","volume":"52","author":"Foweraker","year":"2011"},{"issue":"1","key":"10.1002\/14651858.CD012733.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1183\/13993003.01567-2015","article-title":"Bronchiectasis: how to be an orphan with many parents?","volume":"47","author":"Goeminne","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0146|cit146","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"3","key":"10.1002\/14651858.CD012733.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/1817-1737.82443","article-title":"Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis","volume":"6","author":"Habesoglu","year":"2011","journal-title":"Annals of Thoracic Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012733.pub2-BIB0148|cit148","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011825","article-title":"Adverse events in patients taking macrolide antibiotics versus placebo for any indication","author":"Hansen","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD012733.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection","volume":"189","author":"Haworth","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0150|cit150","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD012733.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"pii: 1700051","DOI":"10.1183\/13993003.00051-2017","article-title":"Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research","volume":"49","author":"Hill","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"8","key":"10.1002\/14651858.CD012733.pub2-BIB0152|cit152","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001392.pub3","article-title":"Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults","author":"Hnin","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012733.pub2-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jcrc.2013.04.008","article-title":"Previous antibiotic exposure and evolution of antibiotic resistance in mechanically ventilated patients with nosocomial infections","volume":"28","author":"Hui","year":"2013","journal-title":"Journal of Critical Care"},{"issue":"3","key":"10.1002\/14651858.CD012733.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40258-013-0027-z","article-title":"Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective","volume":"11","author":"Joish","year":"2013","journal-title":"Applied Health Economics and Health Policy"},{"issue":"4","key":"10.1002\/14651858.CD012733.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1378\/chest.11-0679","article-title":"The burden of disease in pediatric non-cystic fibrosis bronchiectasis","volume":"141","author":"Kapur","year":"2012","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD012733.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jcf.2012.03.010","article-title":"A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis","volume":"11","author":"Littlewood","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD012733.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.07-0490","article-title":"Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis","volume":"132","author":"Mart\u00ednez-Garc\u00eda","year":"2007","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD012733.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.arbres.2017.07.016","article-title":"Spanish guidelines on treatment of bronchiectasis in adults","volume":"54","author":"Mart\u00ednez-Garc\u00eda","year":"2018","journal-title":"Archivos de Bronconeumolog\u00eda (English Edition)"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1471-2466-14-107","article-title":"Treatment adherence and health outcomes in patients with bronchiectasis","volume":"14","author":"McCullough","year":"2014","journal-title":"BMC Pulmonary Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012733.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"273-83","DOI":"10.1111\/eva.12196","article-title":"The fitness costs of antibiotic resistance mutations","volume":"8","author":"Melnyk","year":"2015","journal-title":"Evolutionary Applications"},{"issue":"7","key":"10.1002\/14651858.CD012733.pub2-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"491-9","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicinin non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl1","key":"10.1002\/14651858.CD012733.pub2-BIB0163|cit163","first-page":"i1-58","article-title":"British Thoracic Society Guidelines for non-CF bronchiectasis","volume":"65","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"issue":"3","key":"10.1002\/14651858.CD012733.pub2-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"pii: 1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD012733.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study","volume":"47","author":"Quint","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD012733.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1183\/20734735.007516","article-title":"Global impact of bronchiectasis and cystic fibrosis","volume":"12","author":"Redondo","year":"2016","journal-title":"Breathe"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0167|cit167","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"6","key":"10.1002\/14651858.CD012733.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1183\/13993003.00954-2015","article-title":"Bronchiectasis in Germany: a population-based estimation of disease prevalence","volume":"46","author":"Ringshausen","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.rmed.2010.02.022","article-title":"Trends in bronchiectasis mortality in England and Wales","volume":"104","author":"Roberts","year":"2010","journal-title":"Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012733.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1513\/AnnalsATS.201310-335OC","article-title":"A novel microbiota stratification system predicts future exacerbations in bronchiectasis","volume":"11","author":"Rogers","year":"2014","journal-title":"Annals of the American Thoracic Society"},{"issue":"4","key":"10.1002\/14651858.CD012733.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1378\/chest.10-0099","article-title":"Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006","volume":"138","author":"Seitz","year":"2010","journal-title":"Chest"},{"issue":"12","key":"10.1002\/14651858.CD012733.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD012733.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/adc.2004.066472","article-title":"New Zealand national incidence of bronchiectasis \"too high\" for a developed country","volume":"90","author":"Twiss","year":"2005","journal-title":"Archives of Disease in Childhood"},{"issue":"4","key":"10.1002\/14651858.CD012733.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.cpm.0000171422.98696.ed","article-title":"Prevalence and economic burden of bronchiectasis","volume":"12","author":"Weycker","year":"2005","journal-title":"Clinical Pulmonary Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012733.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1183\/09031936.97.10081754","article-title":"Effect of sputum bacteriology on the quality of life of patients with bronchiectasis","volume":"10","author":"Wilson","year":"1997","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012733.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"European Respiratory Journal"},{"issue":"9842","key":"10.1002\/14651858.CD012733.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD012733.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T06:51:14Z","timestamp":1635490274000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012733.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,6,3]]},"references-count":177,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012733.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,3]]}}}